Clinical Trials Directory

Trials / Completed

CompletedNCT01526252

Reference Population for Speckle Tracking Imaging

Establishing a Reference Population for Normal Left Ventricular Function Parameters to Validate the Use of Two Dimensional Speckle Tracking Imaging Software in the Scar Study

Status
Completed
Phase
Study type
Observational
Enrollment
91 (actual)
Sponsor
Ottawa Heart Institute Research Corporation · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Accepted

Summary

The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (2DSTE) is growing, but data relevant to the population in the SCAR study is minimal. Accumulation of data relevant for a population of subjects will provide a set of normal values for interpretation of 2DSTE and minimize any influences from differences in data produced from different companies. This data may also assist other researchers investigate other cardiac diseases and abnormalities.

Conditions

Timeline

Start date
2011-12-01
Primary completion
2012-07-01
Completion
2015-01-01
First posted
2012-02-03
Last updated
2017-04-24

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01526252. Inclusion in this directory is not an endorsement.

Reference Population for Speckle Tracking Imaging (NCT01526252) · Clinical Trials Directory